Nathan Sanicharane has been appointed as new business development manager for the chemicals sector at safety equipment specialist Draeger Safety UK.
Sanicharane has a Masters degree in Chemistry and has spent four years working in drugs development. He also has nearly five years’ experience in selling chromatography and specialist chemicals.
Draeger hires new business development manager
Nathan Sanicharane takes up the role
You may also like
Regulatory
NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages
NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience
Regulatory
testo Saveris 1 update automates environmental monitoring workflows for pharma compliance
Testo Saveris, global leader in measurement solutions, has announced the latest software update for its testo Saveris 1 Environmental Monitoring System, designed to address the evolving needs of the pharmaceutical industry by delivering reliable and precise monitoring of key metrics, including temperature and humidity
Regulatory
FDA accepts first quality control standard for mesenchymal stromal cells
The FDA has accepted the first dedicated quality control protocol for mesenchymal stromal cells, recognising the Tasly 3P Characterisation Assay and setting a new regulatory benchmark for MSC safety and clinical performance
Regulatory
3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites
The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
Regulatory
Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV
Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting